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Background: To assess the influence of sentinel lymph nodes (SNs) SPECT/CT and 18 F-choline (18 F-FCH) PET/CT in
radiotherapy (RT) treatment planning for prostate cancer patients with a high-risk for lymph node (LN) involvement.
Methods: Twenty high-risk prostate cancer patients underwent a pelvic SPECT acquisition following a transrectal
ultrasound guided injection of 99mTc-Nanocoll into the prostate. In all patients but one an 18 F-FCH PET/CT for RT
treatment planning was performed. SPECT studies were coregistered with the respective abdominal CTs. Pelvic SNs
localized on SPECT/CT and LN metastases detected by 18 F-FCH PET/CT were compared to standard pelvic clinical
target volumes (CTV).
Results: A total of 104 pelvic SNs were identified on SPECT/CT (mean 5.2 SNs/patient; range 1–10). Twenty-seven
SNs were located outside the standard pelvic CTV, 17 in the proximal common iliac and retroperitoneal regions
above S1, 9 in the pararectal fat and 1 in the inguinal region. SPECT/CT succeeded to optimize the definition of
the CTV and treatment plans in 6/20 patients due to the presence of pararectal SNs located outside the standard
treatment volume. 18 F-FCH PET/CT identified abnormal tracer uptake in the iliac LN region in 2/19 patients.
These abnormal LNs were negative on SPECT/CT suggesting a potential blockade of lymphatic drainage by
metastatic LNs with a high tumour burden.
Conclusions: Multimodality imaging which combines SPECT/CT prostate lymphoscintigraphy and 18 F-FCH PET/CT
identified SNs outside standard pelvic CTVs or highly suspicious pelvic LNs in 40% of high-risk prostate cancer
patients, highlighting the potential impact of this approach in RT treatment planning.
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Prostate cancer patients with a high-risk of nodal in-
volvement are most frequently treated with an associ-
ation of androgen deprivation and radiotherapy (RT) to
the prostate, seminal vesicles, and pelvic lymph nodes
(LNs) [1,2]. The consensus guidelines of the Radiation
Therapy Oncology Group (RTOG) recommend the irra-
diation of the distal common iliac, presacral (S1-S3),
external iliac, internal iliac, and obturator LN regions
[3]. However, lymph from the prostate may also drain to* Correspondence: hansjorg.vees@hcuge.ch
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reproduction in any medium, provided the ornodes in the pararectal, internal pudendal, and anterior
abdominal regions [4,5].
Lymphoscintigraphy of the prostate with 99mTc-Nano-
coll enables the detection of sentinel lymph nodes (SNs)
with a very high sensitivity of 93% to 98% [5,6]. Different
studies have shown that registered images of SPECT and
CT can detect more SN than a lymphoscintigraphy alone
[7,8]. Although, there is lack of consensus regarding the
value of PET imaging in the primary diagnostic of pros-
tate cancer, PET/CT using 18 F- or 11C-labeled acetate or
choline has shown a high potential in visualizing local
and regional recurrence in prostate cancer with a high
sensitivity and specificity [9].
The aim of this study was to evaluate the potential of
SN SPECT/CT in RT treatment planning in prostated. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Disease characteristics of the patient population
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http://www.ro-journal.com/content/7/1/134cancer patients with a high-risk for LN involvement. As
no pathological verification of the SNs was planned in this
study, a 18 F-choline (18 F-FCH) PET/CTs was performed
in order to get additional information on the potential
metastatic infiltration of the SPECT positive SNs.
Methods
This prospective study was approved by the Ethical
Committee at the Geneva University Hospital. A signed
informed consent was obtained from all patients partici-
pating in the study. Given that 18 F-FCH tracer is not
registered in Switzerland, it was administered under the
ruling of “special use”, which requires approval on a
patient by patient basis by the Swiss federal authorities
(Swissmedic and the Federal Office of Public Health,
Section of Radioprotection).
Twenty prostate cancer patients were included in the
study from May 2007 to April 2009. Eligible patients
were selected based on a biopsy-confirmed adenocarcin-
oma of the prostate with a high risk for LN metastases.
The estimated risk for pelvic LN involvement was ≥20%
according to the predictive model developed by Roach
et al. [10]. A negative metastatic work-up was obtained
for every patient before entering the study with an
abdominal CT, and a bone scan. After entering the
study, all patients underwent a prostate SPECT/CT lym-
phoscintigraphy and all but one patient had an add-
itional 18 F-FCH PET/CT. The decision to incorporate
18 F-FCH PET/CT in the study was taken according to
an amendment to the study established after the inclu-
sion of the first patient.
The median age was 67 years (range, 51–74) and the
median PSA at diagnosis was 30.5 ng/ml (range,6.4–
66.5). The clinical characteristics and referral patterns of
the patient population are summarized in Table 1.
Lymphoscintigraphy technique and SPECT/CT fusion
imaging and interpretation
Four aliquots, of 50 MBq in 1 mL 99mTc-nanocolloid
(Nanocoll1, GE Healthcare, Amersham Health, Piscat-
away, NJ) were injected into both lobes of the prostate
using a Chiba needle (0.70 x 220 mm) under transrectal
ultrasound guidance (Toshiba APLIO SSA-770A) apply-
ing 1 fraction in the apical and 1 in the basal part of
each lobe. All injections were performed by an experi-
enced radiologist (AC) under antibiotic coverage. Spill of
the radiocolloid into the rectum could be avoided. All
patients were asked to empty their bladder after the in-
jection. Immediately before the imaging, the patients’
skin was marked with 3 fiducial body markers (Multi-
Modality NucMed/PET Markers MM3003, IZI Medical
Products, Baltimore, MD) containing 0.1–0.2 MBq of
99mTcO4 (pertechnetate) over the pelvis. After early planar
images, SPECT of the pelvis and abdomen (γ camera,IRIX, Philips, Milpitas, CA) was performed 90 minutes
after tracer injection. All distinctly visible LNs on SPECT
were defined as SNs.
The SPECT imaging was performed on a dedicated RT
table in the same position as the treatment planning
PET/CT or CT for the one patient who didn’t had the
PET/CT. The acquisition protocol for SPECT was stan-
dardised (3 Head Gamma Camera Irix (Marconi),
LEGAP collimator, 60 frames of 60 sec. each in steps of
6°, 128 x 128 matrix) as was the image post processing
(count truncation of injection site maxima, iterative
reconstruction (OSEM), 4–20 iterations, Butterworth
post filtering, reconstructed slice thickness 4.7 mm).
Reconstructed transverse data sets were overlain with
the corresponding CT. Image fusion was performed by
the use of body markers using commercially available
software (Syngo 3D Fusion TM, Siemens, Erlangen,
Germany). The fusion accuracy (5 mm) and the 99mTc-
activity calibration were experimentally validated by
preceding phantom studies. SPECT calibration was per-
formed on an object of similar shape and size as the
simulated object and surrounding tissues (EMA IEC/
2001 image quality body phantom) with spherical inserts
suspended by plastic rods. The spheres were filled with
99mTc-nanocolloid activity with ascending concentration
ranging from 0.7–2.8 MBq. In all cases, image fusion of
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medicine specialist (CS). Images were read by two exami-
ners in consensus reading to determine the number
of SNs, pelvic side, and anatomic region according to the
nodal atlas of Martinez-Monge et al. [11]. Each sentinel
node was defined in transverse, sagittal, and coronal
views.18 F-fluorocholine PET/CT scanning
GMP 18 F-fluorocholine (fluorocholine-fluoromethyl-
dimethyl-2-hydroxyethyl-ammonium) was obtained from
the Centre of Radiopharmacy, University Hospital of
Zürich, Switzerland.
All but one patient had a PET/CT on a LSO-based
PET/CT scanner (Biograph 16, Siemens Medical Solu-
tion, Erlangen, Germany) operating in 3D mode. All
patients were fasted for at least four hours before the
18 F-FCH PET/CT. The 18 F-FCH PET/CT was per-
formed in RT treatment position on a dedicated RT
table equipped with a set of three triangulation lasers
(central and laterals), and intrinsic supports units similar
to those used for standard CT-based virtual simulation.
After the CT scan, patients were injected 300 MBq
18 F-fluorocholine and immediately underwent a con-
tinuous list-mode PET acquisition of the pelvis during
10 minutes. Following the list mode acquisition a stand-
ard whole-body PET study was performed from the mid
thigh to the skull over 7 to 8 bed positions of 3 to 4 min-
utes each, depending on patient size and weight. Two
additional late PET acquisitions of 5 minutes of prostate
bed and adjacent pelvic region were acquired immediately
after whole-body PET (~40 minutes after tracer injection).
A detailed description of the PET scanning technique has
been previously published by our group [12].RT planning
Clinical target volumes (CTV) were drawn on series of
CT slices by an experienced radiation oncologist and
were defined according to the RTOG guidelines on pel-
vic lymph node volumes [3]. The CTV included the
prostate, the seminal vesicles, the distal common iliac,
presacral, external iliac, internal iliac, and obturator LNs.
The obturator and internal iliac LNs were contoured
from the obturator foramen up to the distal common
iliac vessels at the level of the upper aspect of the L5/S1
interspace. The external iliac LNs were drawn from the
level where the external iliac vessels cross the inguinal
ligament to the same upper level of the internal iliac
nodes. The presacral LNs were drawn between S1 and
S3. Organs at risk were delineated as well using the CT
images, and included the rectum, the bladder, the bowel,
and both femoral heads. SPECT images were highlighted
and coregistered with the CT.Statistical analysis
Statistical analyses and curve fitting were performed
using SPSSW (version 15.0, SPSS Inc., Chicago, IL, USA).
The level of statistical significance was 0.05.
Results
Both lymphoscintigraphy and 18 F-FCH PET/CT studies
were well tolerated with no toxicity. A total of 104 SNs
were detected after the injection of 99mTc-nanocolloid,
thus a mean of 5.2 LN/patient (range, 1–10). SNs
drained most frequently to external iliac and common
iliac regions (Table 2). In 14 patients, however, 27 SNs
were located outside the pelvic CTV region: nine para-
rectal, 1 right inguinal and 17 in the retroperitoneal
region above S1. Patients with retroperitoneal SNs pre-
sented in addition a median of 7 (range, 3–10) SNs in
the pelvis compared to a median of only 3 (range, 1–5)
pelvic SNs in those patients with no SNs in the retro-
peritoneal region (Table 2). The remaining 77 SNs were
all included in the CTV (see Table 3). All SNs were non-
suspicious according to metabolic and morphologic criteria:
normal size and shape, and negative 18 F-FCH uptake.
The location of the SNs was evaluated according to a
4-field pelvic standard treatment plan. The paraaortic
and the right inguinal SNs were disregarded for treat-
ment planning. Two of the pararectal SNs received at
least 95% of the prescribed radiation dose (patient no. 1
and 9). The remaining SNs found in the pararectal re-
gion and outside the original CTV were included in an
enlarged new CTV. They accounted for 7 SNs in 6
patients (30%). A fusion image of SPECT and planning
CT of a pararectal SN is shown in Figure 1.
In all patients but two undergoing 18 F-FCH PET/CT
studies no suspected regional LN metastases were
detected. In the two patients with an abnormal tracer
uptake in the LN region, the first one (patient no. 3) had
a suspect LN metastasis in the left internal iliac area
with a SUVmax of 2.6 and the second one (patient no. 9)
had a suspect LN metastasis in the right external iliac
area with a SUVmax of 4.5. SPECT/CT studies did not
show any 99mTc-uptake in both suspected metastatic
LNs based on 18 F-FCH PET/CT studies probably be-
cause of a lymphatic drainage blockade secondary to a
massive tumour invasion of the concerned LNs. The
suspected LN metastases were both located inside the
standard CTV and were treated with an additional boost
dose (Figure 2). All 18 F-FCH PET/CT studies were nega-
tive for distant disease.
Discussion
Most SNs in our study were located inside a standard
CTV for pelvic LNs. However, 27 SNs were detected
outside the CTV and only 2 were expected to receive at
least 95% of the prescribed radiation dose with a 4-field
















1 1 1 1 3
2 1 2 3
3 1 1 2 2 1 7
4 1 1 2 1 1 1 7
5 1 2 2 1 2 8
6 2 1 1 1 1 6
7 1 1 1 1 4
8 1 1 1 3
9 1 2 2 5
10 3 3
11 1 2 2 1 2 8
12 1 2 2 3 1 9
13 1 1 1 3 1 7
14 2 2 4
15 2 1 1 3 2 1 10
16 1 1 1 1 4
17 1 1 1 3
18 1 1
19 1 2 2 5
20 1 2 1 4
Total 0 2 1 9 9 11 8 28 19 8 9 104
Abbreviation: SV: seminal vesicle lymph plexus.
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(70%) presented with SNs outside the pelvic CTV
region. Unlike Ganswindt et al. and Krengli et al. we
observed a relatively higher number of SNs in the retro-
peritoneal region [6,13]. Indeed, paraaortic SNs were
observed in 55% of our patients. One patient presented
a SN in the right inguinal region. The SNs in the retro-
peritoneal region and in the right inguinal bed were
excluded from the treatment volume as described above.Table 3 Localization of sentinel lymph nodes in relation
to the pelvic CTV






Internal iliac 8 0
External iliac 28 0
Distal common iliac 19 0
Left paraaortic 0 8
Right paraaortic 0 9
Total 77 27
Abbreviation: VS: seminal vesicle lymph plexus.Wengenmair et al. showed that the accumulation of
99mTc in LNs is highly variable and is generally com-
pleted 90 minutes after tracer injection [14]. We defined
the SNs in the SPECT according to their results and
found a higher number of SNs in those patients with the
presence of retroperitoneal SNs. This period is maybe too
long in some cases and several of the positive LNs in the
SPECT are no longer part of the first step lymph drainage
of the prostate but rather a second step drainage. The
results of a retrospective study by Vermeeren et al. were
in concordance with this hypothesis [15]. They showed
that the incidence of LN metastases in paraaortic SNs is
low. Treating the paraaortic region prophylactically based
on SN positivity may not be beneficial but may rather in-
crease dangerously the risk of radiation induced intestinal
toxicity. However, a drawback of this study is the lack of
pathological verification of the SNs.
The appearance of inguinal LN metastasis from pros-
tate cancer is very rare and may occur mostly in patients
with advanced metastatic disease [16]. SNs in the
inguinal region have only been described in a series of
3 patients with SNs in the ventral abdominal wall and in
only one of these patients the presence of tumour was
confirmed on pathological examination [4]. In our study
only one suspicious inguinal SN was observed. This
patient had a surgical intervention for inguinal hernia
Figure 1 (A) Fusion image of SPECT and planning CT (patient
no. 6) showing a transverse section of two pararectal and a
right external iliac SN. (B) Axial view of the standard nodal clinical
target volume (CTV) (green) and the pararectal SNs (yellow).
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http://www.ro-journal.com/content/7/1/134with potential subsequent disruption and rerouting of
lymphatic pathways resulting in an aberrant lymphatic
drainage to the inguinal LN region and was not included
in the treatment volume. We did not observe SNs in the
internal pudendal region. The published incidence of
SN in the internal pudendal region is very low, ranging
between 1–2% [6].
Serum PSA, clinical stage, and Gleason score are
widely recognized predictors of aggressiveness of pros-
tate cancer. In patients with a high-risk profile, theinclusion of the pelvic LNs in the RT treatment volume
may improve the rate of disease free survival compared
to those treated to the prostate alone [10]. The prostate
SN as the first lymphatic echelon receiving lymph drain-
age is the most likely site for early metastases, especially
in high-risk patients. Although, SPECT/CT lymphoscin-
tigraphy has shown a high sensitivity in detecting SNs,
there is at the present time no recommendation even for
high-risk prostate cancer patients to irradiate the whole
lymph drainage of the prostate. Indeed, the inclusion of
all possible lymph drainage would increase the treatment
volume excessively and would represent a too high-risk
of radiation induced intestinal and urinary toxicity. The
RTOG trial 75–06 was unable to detect significant dif-
ferences in prostate cancer patients with detectable dis-
ease confined to the pelvis and treated with or without
elective paraaortic irradiation [17].
Treatment optimization in RT offers the possibility of
highly conformal radiation dose distribution by using
techniques such as intensity-modulated RT (IMRT),
which is superior to straight three-dimensional con-
formal RT in limiting the volume of bowel, bladder and
rectum within the high- to intermediate-dose region
opening the potential for dose escalation [18]. The deliv-
ery of a prophylactic irradiation dose to the distant para-
aortic nodes can be safely performed using IMRT
technique. One of the known drawbacks of IMRT tech-
nique is that it may increase the risk of geographical
miss of LNs, which are outside the recommended CTV.
The evaluation of SN SPECT imaging in prostate cancer
patients has shown that SNs may be excluded from the
CTV in 25–76% of cases. This risk may be even higher
when treating with IMRT [6,13].
The inclusion of pelvic SNs in the CTV for prostate
cancer patients with a high risk of LN metastases offers
the opportunity to better adapt to the individual variabil-
ity of the lymph drainage and may minimize the risk
of missing the irradiation of metastatic LNs. Transrectal
injection of 99mTc-Nanocoll in the prostate guided by
ultrasound is feasible and without major complications
and implies the possible indication for this approach in
high-risk prostate cancer patients. One may consider
a drawback of this study that a post-acquisition co-
registration between SPECT and CT images was per-
formed. However both imaging studies were carried out
on a dedicated RT table using fiducial body markers by
experienced radiation therapy technologists trained spe-
cially for this purpose. The SPECT/CT fusion was always
possible without major problems.
Gutman et al., recommended 18 F-FCH PET/CT in
patients with a high risk of regional or metastatic disease
[19]. Beheshti et al. revealed that the sensitivity and spe-
cificity of 18 F-FCH PET/CT in the detection of malig-
nant LNs were 45 and 96%, respectively [20]. In our
Figure 2 (A) 18 F-FCH PET/CT (patient no. 3) showing a transverse section with a suspicious lymph node metastasis in the left internal
iliac region. (B) The corresponding color wash dose distributions for the planning target volume (PTV).
Vees et al. Radiation Oncology 2012, 7:134 Page 6 of 7
http://www.ro-journal.com/content/7/1/134study we observed one suspicious regional LN metasta-
sis in two patients, respectively. These two LNs with an
abnormal 18 F-FCH uptake were not detected as SNs via
SPECT, perhaps showing a limitation of SPECT. One hy-
pothesis is that these small LNs could be heavily infil-
trated by prostate cancer hampering the lymph path.
A pathological evaluation of such lymph nodes might
have confirmed this hypothesis. Although, 18 F-FCH
PET/CT cannot yet be recommended as a standard diag-
nostic tool as part of the RT treatment planning in high-
risk prostate cancer patients, the detection of these
suspicious LNs in the pelvic region allowed to identify a
target to be boosted with a high dose after the irradi-
ation of the standard pelvic CTV. Further studies are
required including extended pelvic lymph node dissec-
tion to evaluate the impact of combined 18 F-FCH PET/
CT and SPECT/CT. Such studies should clarify if such
multimodal imaging strategy leading to improvement in
the detection of a geographic misses.Conclusion
Multimodality imaging combining SPECT/CT prostate
lymphoscintigraphy and 18 F-FCH PET/CT identified
SNs outside standard pelvic CTVs or highly suspicious
pelvic LN metastases in a majority of high risk pro-
state cancer patients. Treatment planning was mod-
ified in 40% of patients due to the observation of
pararectal SNs in 6 patients (30%) and a suspicion of LN
metastases in PET/CT in 2 patients (10%) demonstratingthe potential impact of this approach in RT treatment
planning.
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